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Abstract
Background: Fragile X Syndrome (FXS) is the second cause of intellectual disability after Down syndrome and the
most prevalent cause of intellectual disability in males, affecting 1:5000–7000 men and 1:4000–6000 women. It is
caused by an alteration of the FMR1 gene, which maps at the Xq27.3 band: more than 99% of individuals have a
CGG expansion (>200 triplets) in the 5′ UTR of the gene, and FMR1 mutations and duplication/deletion are responsible
for the remaining (<1%) molecular diagnoses of FXS. The aim of this review was to gather the current clinical and
molecular knowledge about FXS to provide clinicians with a tool to guide the initial assessment and follow-up of
FXS and to offer to laboratory workers and researchers an update about the current diagnostic procedures.
Discussion: FXS is a well-known condition; however, most of the studies thus far have focused on neuropsychiatric
features. Unfortunately, some of the available studies have limitations, such as the paucity of patients enrolled or bias
due to the collection of the data in a single-country population, which may be not representative of the average
global FXS population. In recent years, insight into the adult presentation of the disease has progressively
increased. Pharmacological treatment of FXS is essentially symptom based, but the growing understanding of
the molecular and biological mechanisms of the disease are paving the way to targeted therapy, which may
reverse the effects of FMRP deficiency and be a real cure for the disease itself, not just its symptoms.
Conclusions: The clinical spectrum of FXS is wide, presenting not only as an isolated intellectual disability but as
a multi-systemic condition, involving predominantly the central nervous system but potentially affecting any apparatus.
Given the relative high frequency of the condition and its complex clinical management, FXS appears to have an important
economic and social burden.
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Background
Fragile X Syndrome (FXS, OMIM #300624), also known
as Martin-Bell Syndrome, was first described in 1943
by Martin and Bell as a form of intellectual disability
(ID) following an X-linked inheritance pattern [1]. In
1969, Lubs first reported a distinct fragile site on the X
chromosome that segregated with ID in 3 generations
of a family, and in 1991, the association of the Xq27.3
fragile site with X-linked ID was confirmed [2, 3].
Therefore, FXS was defined as a clinical and cytogenetic
entity and acquired its current name. Currently, it is
known to be the second cause of ID after Down Syndrome
(2.4% of all IDs), the first cause of inherited ID and the
most prevalent cause of ID in males [4, 5]. The actual
worldwide prevalence is estimated to range between
1:5000–7000 men and 1:4000–6000 women [5].
The diagnosis of FXS is based on the detection of an
alteration of the Fragile X Mental Retardation-1 gene
(FMR1), which maps at the Xq27.3 band [2]. More than
99% of individuals with FXS have an FMR1 loss-of-function
caused by an increased number of CGG trinucleotide re-
peats in the 5′ untranslated (5′ UTR) region (typically >200
triplets). This allelic constitution is called a full mutation
(FM) and produces the expression of the cytogenetic fragile
site (FRAXA). Its result is a hypermethylated state of
the FMR1 promoter, with consequent inhibition of FMR1
transcription and loss or heavy reduction of the protein
product (FMRP). Therefore, the FXS phenotype is a direct
consequence of the absence of FMRP; different types of
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FMR1 alterations (deletions encompassing the gene, intra-
genic deletions/duplications, single-nucleotide variants)
are responsible for the remaining (<1%) molecular diagno-
ses of FXS [6].
The normal number of repeats within the FMR1 gene
ranges from 5 to 44; a repeat number of 45–54 is con-
sidered to be a grey zone. A repeat number of 55–200 is
called pre-mutation (PM), and it is associated with
pathological conditions that differ from FXS : premature
ovarian failure (POI) in females and fragile X - associated
tremor/ataxia syndrome (FXTAS) in males (less frequently
also in females) [6]. Given the phenotype breadth of the
FMR variations, typical of trinucleotide expansion disease,
we chose here to provide a review that is limited to the
complete FXS phenotype, which affects individuals carry-
ing a FM allele.
FXS inheritance does not follow a Mendelian pattern,
but it depends on the number of trinucleotide repeats
within the promoter of the FMR1 gene [6]: a transition
from the PM to FM allele can occur because of the ex-
pansion phenomenon during the transmission of the
maternal (very rarely of the paternal) X chromosome
carrying a PM to her children [3, 4]. The frequency of
individuals with the PM allele in the total population is
approximately 1:850 for males and 1:257–300 for females
[5, 7] - i.e., one in 300 females randomly chosen among
the general population can potentially generate an affected
male child.
Affected men have a typical phenotype, characterized
by ID, long face, large and protruding ears, and macro-
orchidism [4, 6, 8]. Females heterozygous for the FM al-
lele have a 30% chance of having a normal intelligence
quotient and a 25% chance of having ID with an IQ < 70;
nonetheless, they can present learning deficits and emo-
tional difficulties [4]. The phenotype in females is strongly
connected to the X inactivation (XCI) pattern.
However, FXS is much more than a simple ID; it is a
multi-systemic condition that can potentially affect any
apparatus because FMRP is widely expressed. The aim
of this review was to gather the current clinical and
molecular knowledge about FXS to provide clinicians
with a tool to guide the initial assessment and follow-up
of FXS and to offer laboratory workers and researchers
an update regarding the current diagnostic procedures.
Discussion
General clinical features
Generally, prenatal and neonatal diagnoses are not possible
with a negative family history because of the lack of ultra-
sound and clinical findings. At birth, the height, weight,
and head circumference of FXS children are within the
normal range [9]. The most prominent clinical features
of the condition are summarized in Table 1. The height
and weight seem to follow the normal growth curves;
Table 1 Clinical features of FXS males [4, 7, 9, 11, 13, 17, 18, 24,
26, 27, 32, 34, 36, 37, 51]
Features Frequency
Face Long/Narrow face 83%
Macrocephaly 81%
Prominent ears 72–78%
High-arched palate 94%
Prominent jaw 80%
Facial hypotonia NA
Eye puffiness NA
Closely spaced eyes NA
Long palpebral
fissures
NA
Epicanthal folds NA
Flat nasal bridge NA
Broad nose NA
Broad philtrum NA
Central nervous
system
EEG anomalies 74%
Epilepsy 10–20%
Brain MRI anomalies Up to 50% of patients with
neurologic comorbidities
Neuropsychiatric
involvement
Psychomotor delay ~100%
ID ~100%
Aggressiveness 90%
Attention problems 74–84%
Hyperactivity 50–66%
Anxiety Disorder 58–86%
ASD 30–50%
Sleep problems 30%
ADHD 12–23%
Depression 8–12%
Musculoskeletal
system
Joint hypermobility 50%
Pectus excavatum 50%
Flat feet 29–69%
Spine deformity 6–9%
Cardiovascular Mitral valve
anomalies
3–12%
Aortic root dilatation 25%
Eye Refractive errors 17–59%
Strabismus 8–40%
Nystagmus 5–13%
Other Macroorchidism 63–95%
Obesity/overweight 53–61%
Recurrent otitis
media
47–97%
Gastrointestinal
complaints
31%
Soft skin NA
Abbreviations: NA not available, ID intellectual disability, ASD
autism spectrum disorder, ADHD anxiety disorder/hyperactivity
disorder
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otherwise, the head circumference tends to reach the
higher centiles: in prepubertal age, the majority of FXS
children develop macrocephaly, with a head circumference
larger than the 50th percentile [4, 6, 9]. The facial charac-
teristics become more distinctive in early childhood, when
the patients start showing a long narrow face and promin-
ent ears [4, 9, 10]. This latter sign is one of the hallmarks
of FXS, but it is often a relative parameter, as the narrow-
ness of the faces of some affected males exaggerates their
ear prominence [10]. Other reported facial features are the
prominence of the jaw, a high-arched palate, puffiness
around the eyes, long palpebral fissures, closely spaced
eyes, epicanthal folds, strabismus, flat nasal bridge, broad
nose, broad philtrum, and facial hypotonia (demonstrated
by slackness of the lower jaw) [4, 6, 8–10] (Fig. 1). Notably,
not all facial features are recognizable at a young age
(most have been recorded only after puberty), and ap-
proximately 30% of young children with FXS will not have
obvious dysmorphic features [6, 10].
The most important clinical abnormality associated
with defects of the FMR1 gene is global developmental
delay/ID. The psychomotor delay involves both walking
age (mean = 2,12 years) and age at first words (mean =
2,43 years) [11]. Both males and females with FXS present
a wide range of learning disabilities in the context of nor-
mal, borderline IQ or mild to severe ID [12]. The IQ of
males with FM varies with studies, with a mean value of
40–51 [11–13]; 68% of FM males have an IQ score lower
than 50, while 18% have a score above 70 [11]. The IQ
score directly correlates with the level of FMRP production:
higher levels of FMRP are found in individuals with an IQ
above 70, showing only moderate emotional and learning
difficulties [4, 14, 15]. Similarly, those individuals with
“size-mosaicism” (full mutation plus premutation, grey zone
or normal alleles) have higher IQs than those without mo-
saicism [15]. Females with FM present a wider range of
phenotypic characteristics than men, depending on the XCI
pattern: 70% of FM women present with some degree of
cognitive impairment [4].
Neurological features
An important comorbidity in FXS is epilepsy. Reports have
suggested a prevalence of seizures among FXS children,
present in 10–20% in boys and 5–10% in girls [13, 16, 17].
Complex partial seizures have been reported to be the most
frequent among FXS patients with epilepsy (89.3%) [13, 16],
followed by generalized tonic-clonic seizures (46.4%), and
simple partial seizures (25%). The latter type is always asso-
ciated with another type of epilepsy; febrile convulsions
have been reported in 7.1% of patients with epileptic
seizures [13]. The age of onset is usually between 2 and
10 years, and this comorbidity typically disappears with
growth, although 25% of FXS patients continue to have
epilepsy into their adult years [13, 16]. Seizures have
usually a low frequency of recurrence and sometimes
manifest themselves following intercurrent infections
or exposure to other environmental factors [13]. Epilepsy
usually has a good response to therapy [13, 16]. Most pa-
tients control their seizures with antiepileptic drugs
(AEDs); only 7% of the patients need more than one drug,
and 10% of the patients do not need any therapy [13].
Independently from epilepsy, patients with FXS also
have a higher prevalence of EEG abnormalities (74%)
[13, 18]; these abnormal EEG findings, however, may not
always manifest with seizures and/or a subsequent diag-
nosis of epilepsy. In a study by Hear et al., 47% of FXS
patients exhibited slowing of the posterior dominant
rhythm for age, and 42% had focal spikes from various
anatomic regions [18]. Nevertheless, consistent with
seizure remission with age, 35% of children showed
normalization of the EEG background after the age of
8 years, and when present, they are more often nonspe-
cific and limited to only one location [13, 18].
MRI is usually normal [13, 18]. When anomalies are
found, these are more frequently diffuse atrophy and
cortical thickness, increased whole hemispheric and lobar
cortical volume, and increased cortical complexity [13, 19].
These aspects are consistent with the decreased pruning
and increased spine density and length and with the pres-
ence of an immature spine, as reported in FXS patients and
mice [19–21].
Further reported findings are atrophy of the cerebellar
vermis, thinning of the corpus callosum, hippocampal
Fig. 1 An FXS child showing long face, large and prominent ears,
long palpebral fissures, broad philtrum, and facial hypotonia
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anomalies, enlarged fourth ventricle, lacunar infarction
of the basal ganglia, and mesial temporal sclerosis; the lat-
ter describes only cases of refractory seizures due to recur-
rent prolonged episodes of status epilepticus [13, 18]. A
recent study by Hall et al. discovered increased fractional
anisotropy in patients with FXS in the left and right infer-
ior longitudinal fasciculus, right uncinate fasciculus and
left cingulum hippocampus compared with that in con-
trols; additionally, this aspect could be attributed to the
aberrant pruning and axon growth dysregulation, resulting
from FMRP reduction [22]. All of these MRI anomalies in
brain morphology correlate negatively with cognitive
performance in FXS children [19].
Neuropsychiatric features
Over the years, FXS has been associated with several
neuropsychiatric and neuropsychological phenotypes,
showing that ID is rarely presented alone in this disease.
Psychomotor delay is the first sign of an upcoming ID in
the scholar age, and it is quite an early finding. The devel-
opmental profile of infants with FXS deviate from that of
the general population by 6 months of age, involving all
domains of development (fine motor, visual reception, ex-
pressive communication, and receptive communication)
[23]. The average functional level of male patients shows
an improving trend until the age of 25, even remaining
below that of the general population. Then, patients enter
a relatively stable phase until the age of 50; at that time,
the skills of FXS males begin to worsen [24].
FXS patients are considered to be at a high risk of de-
veloping one or more neuropsychiatric disorders. An as-
sociation between autism and FXS was first noted in the
early 1980s, and a growing number of reports of further
neuropsychiatric conditions emerged in the following
years. Among those, the associations FXS/autism and
FXS/Anxiety Disorder Hyperactivity Disorder (ADHD)
are the most studied [11, 17, 25–33].
The autism-like presentation of many FXS males is
known since the earliest study on the psychological
characterization of the syndrome [25]. It is estimated
that 30–50% males and 25% females with FXS have an
Autism Spectrum Disorder (ASD) as a comorbidity
[26, 27, 30]. Some studies suggested that there is an
age-related improvement in some but not all ASD
symptoms across adulthood for FXS men [27, 28]: autism
is diagnosed in approximately 49% of children but 41% of
adolescents/adults [27]. Nevertheless, the ASD-related im-
pairment seems to be less severe in FXS individuals than
in those with non-syndromic ASD [29]. In recent years,
the change in the diagnostic criteria for ASD, due to the
transition from DSM-IV TR to DSM-5 in 2013, is modify-
ing this rate of incidence because the prevalence of ASD
diagnoses is lower using the DSM-5 criteria across all age
and sex groups [28, 30]. Only 50% of males diagnosed with
ASD using the DSM-IV-TR parameter still fulfil the ASD
criteria using the DSM-5. This gap is even broader for
females; only 30% of FXS girls meet an ASD diagnosis
changing from DSM-IV-TR to DSM-5 [30]. Anyway,
given the high prevalence of autistic features in FXS
and the fact that sometimes it represents the only sign
of the syndrome, all children affected by ASD, especially
boys, should be tested for FMR1 [6].
ADHD is considered one of the most common comor-
bidities in FXS, with more than one-half of male patients
fulfilling the diagnostic criteria at some point in their
lives. The prevalence of ADHD spectrum symptoms is
54–59%, a higher rate than that in individuals with iso-
lated ID or different neuropsychiatric disorders [31]. The
complete diagnostic criteria of ADHD are fulfilled by
12–23% of the FXS subjects [11, 32]. Preschool boys
seem not to differ from typically developing controls in
the mean level of ADHD symptoms and reach their peak
at school age (5–6 years) [32].
As part of the ADHD spectrum, isolated hyperactivity
also has a high incidence, with 50–66% of FXS children
being affected [11, 17, 27, 33]; attention problems are
well represented too, with an overall prevalence of
74–84% [17, 27]. Anxiety disorder is another frequent
trait of FXS subjects, with a prevalence that largely
varies with studies in the range of 58–86% [17, 27, 34].
Cordeiro et al. demonstrated that in a group of 58 males
and 39 females with FXS aged 5–33 years, 86.2% of males
and 76.9% of females met the criteria for at least one anx-
iety disorder [34]. Both anxiety and attention problems
seem to follow an increasing trend with age [27].
The same trend also characterizes depression, which is
prevalent in adolescents/adults rather than in children
and has an overall prevalence of 8–12% in FXS individ-
uals [17, 27]. This may not always manifest, but it can
be revealed by withdrawal or increased aggression rather
than by sadness, anhedonia, or irritability [26].
Other common neuropsychiatric conditions are the
following: pervasive developmental disorder [11, 23], ste-
reotypies (mostly hand/finger mannerisms) [11, 35],
sleep problems [36], specific or social phobias [34], se-
lective mutism [34], restricted interests [35], compulsive
and ritualistic/sameness behaviours [35], self-injurious
behaviour [35], and aggressiveness [27]. This latter as-
pect has been fully examined recently by Wheeler et al.,
who demonstrate that 90% of individuals with FXS,
both males and females, were reported to be engaged
in at least one aggressive act in the previous 12 months
[37]. Sleep disorders affect approximately 30% of FXS
children of both sexes and manifest themselves as diffi-
culties falling asleep, frequent night-time awakenings,
and early awakening in the morning [36].
It is then clear that aside from ID, the neuropsychiatric/
neuropsychological profile of FXS is complex, and it has
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been demonstrated that overall, when using DSM-IV-TR
criteria, 73% of FXS patients can be diagnosed with at least
one axis I psychiatric disorder [11]. This incidence can in-
deed be underestimated because the assessment of psychi-
atric symptoms in patients with FXS is often complicated
by limitations in the accuracy of self-reporting and insight,
atypical manifestation of some symptoms in the context of
ID, and the relative lack of validated assessment tools. For
example, limited expressive language and social reciprocity
impairments often prevent a reliable communication of
symptoms. Diagnostic overshadowing occurs when psy-
chiatric symptoms are not appreciated as a co-morbid
problem in a patient with ID but are attributed only to the
disability itself [26].
A real syndrome: multi-systemic involvement
The neurologic/neuropsychiatric presentation certainly
is the hallmark of the syndrome, but FXS also shows an
association of various medical problems that may or may
not be present; however, when manifested, it can worsen
the phenotype and complicate the clinical management of
these patients.
Since the first reports of FXS, it has been clear that
the condition shares some features with the connective
tissue disorder (CTD) spectrum. Although a specific ab-
normality of the connective tissue has not yet been
shown, the prevalence of connective tissue signs has sug-
gested that there is an underlying connective tissue
anomaly, perhaps similar to that observed in CTDs (in
particular, Marfan Syndrome and Ehlers-Danlos Syn-
drome); the precise association between FXS and signs
of connective tissue abnormality still awaits biochemical
and molecular explanation [38]. The skin can be soft
[24, 39, 40], and joint hypermobility is present in about
half of the patients, affecting predominantly the small joints
(mostly metacarpal-phalangeal joints) [6, 24, 39, 40]. Skel-
etal signs may include a high-arched palate, scoliosis, pectus
excavatum, and flat feet [6, 9, 24, 39, 40].
Connective tissue fragility also involves the heart be-
cause FXS patients can develop cardiac defects similar
to those observed in CTDs. Recurrent findings are aortic
root dilatation (approximately 25% of the patients) and
mitral valve prolapse (3–50%) [9, 38–40]; this latter fea-
ture is frequent in the general population but has a
higher prevalence in CTDs. Hyperarousal (i.e., faster
heart rate) and reduced parasympathetic vagal tone have
also been documented [41]. In adult age (>40 years),
FXS patients tend to develop the common cardiovascu-
lar problems shared by the age-matched general popula-
tion, such as hypertension (24.2%) and heart rhythm
disorders (24.2%) [42].
The function of the gastrointestinal system in individ-
uals with FXS has not been well studied yet. Given the
presence of connective tissue signs, hypotonia and con-
nective tissue anomalies could contribute to some of the
gastrointestinal problems reported in this condition, such
as gastro-oesophageal reflux, constipation, and loose
bowel movements. In a study by Utari et al. including FXS
males and females aged 40–71 years, a prevalence of
gastrointestinal problems of 30.6% was reported [42].
Nonetheless, the literature lacks studies documenting an
effective increased incidence of gastrointestinal involve-
ment compared with that in the general population.
The genitourinary system seems to be affected only in
males, where pubertal macroorchidism is considered a
hallmark of the condition, shared by 80-95% of adults,
but it is less common in prepubertal boys [4, 6, 8, 9, 39,
40]. In adult FXS men, the mean testicular volume is ap-
proximately 50 mL (normal mean testicular volume:
<25 mL) [8]. Given the presence of ID, most FXS men
do not have any real fertility complaints, even if 1% of
them have been reported to reproduce [4].
Ocular anomalies are known since the first reports of
the condition and affect at least 25% of FXS children
and a greater number of FXS adults [43, 44]. Strabismus
and refractive errors have a higher prevalence in FXS than
in the general population [6, 8, 24, 45]: that prevalence,
considerably variable with studies, is 8–40% for strabismus
and 17–59% for refractive errors (primarily hyperopia and
astigmatisms, but myopia is also reported) [8, 24, 43, 44,
46]. Nystagmus has been identified as a less rare finding
(5–13%) [43, 46]; other observable ocular features include
palpebral ptosis and convergence insufficiency [46].
FXS children tend to have recurrent otitis media,
which may lead to conductive hearing loss [6, 8, 9, 11].
These patients already have poor expressive language
skills, so it becomes fundamental that any possible oto-
logic problem is promptly treated to avoid interference
with speech improvement [47]. It has been reported that
language skills are better among children who did not
have recurrence of this complication [48].
Metabolic problems are common and well reported,
with obesity and overweight being quite frequent in both
sexes [6, 8, 42]. Studies conducted in FXS adults reported
an incidence of 53–61% for obesity/overweight [42, 49].
Males are more frequently overweight, while women
tend to reach obesity [42]. Furthermore, in males with
FXS, the serum levels of HDL are shifted to lower
numbers across all age ranges, but conversely, their tri-
acylglycerol levels are higher than those of the general
population [49, 50].
Differential diagnosis
The differential diagnosis of FXS includes syndromic
forms of ID but also non-syndromic psychomotor delays/
ID. The differential diagnosis includes Sotos Syndrome,
Prader-Willi Syndrome, Klinefelter Syndrome, and FRAXE
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[6, 51, 52]. These conditions share the following pheno-
typic features with FXS:
– Sotos Syndrome: ID, macrocephaly, behavioural
problems, and epilepsy [6, 51, 53]
– Prader-Willi Syndrome: developmental delay,
elements of facial appearance, sucking problems in
neonatal age, obesity, and genital anomalies [6, 51, 54]
– Klinefelter Syndrome: ID (20%) and genital
anomalies [51]
– FRAXE: ID (generally milder than FXS), language
impairment, hyperactivity, and autistic behaviour
[6, 51].
Angelman and Rett Syndromes may also be considered
for the differential diagnosis, even if their typical presen-
tation differs from that of FXS children. Shared features
are ID, language impairment, and autistic behaviour. An
Array-CGH can be performed to exclude cytogenetic re-
arrangements responsible for ID. When genetic testing
is not helpful, isolated ID, autism, or ADHD must be
considered [52].
The FMR1 gene and FMRP: from triplet expansion to
pathology
FXS is associated with a rare fragile and unsteady site on
Xq27. This site, named FRAXA, was originally observed
as a non-staining gap, break or constriction in the meta-
phase chromosomes placed under selective culture condi-
tions, such as folic acid or thymidine deprivation [2, 55, 56].
In 1991, an association between FXS and alterations of the
FMR1 gene was identified, located at the FRAXA locus [3].
The FMR1 gene product, FMRP, is involved in the regula-
tion of post-transcriptional RNA metabolism, playing an
important role in synaptic plasticity, dendrite and axon de-
velopment, and underlying learning and memory. FMRP
acts as an organizer of both mRNA transport (shuttle pro-
tein), targets mRNA translation (RNA-binding protein) and
is involved in a feedback loop by controlling its own local
protein levels [57].
The absence of FMRP derives, in most cases, from a
dynamic mutation consisting of variable expansion of a
trinucleotide (CGG) repeat in the 5′ UTR of the FMR1
gene. The size of the CGG repeat in normal individuals
ranges between 5 and 44, and it is usually stably transmit-
ted throughout generations. Alleles with 45–54 repeats
are defined as intermediate, borderline or “grey-zone”
(GZ). Carriers of GZ alleles do not show an FXS pheno-
type but can present with peripheral neuropathy, ataxia,
anxiety and/or depression, and clinical symptoms similar
to those of Parkinson patients, including bradykinesia,
rigidity, memory complaints, and a positive response to
dopaminergic medications [58]. PM carriers have a
number of repeats that ranges from 55 to 200. PM
disorders were first identified in 1991 with the discov-
ery of an increased incidence of early menopause (prior
to the age of 40 years) in female carriers [59]. Twenty
percent of PM females manifest an FMR1-related POI
[6], while FXTAS occurs in PM males (rarely in fe-
males) and is characterized by late-onset, progressive
cerebellar ataxia and intention tremor [6, 60]. The ne-
cessary findings to confirm an FXTAS diagnosis are an
FMR1 PM associated with an MRI showing white mat-
ter lesions in the middle cerebellar peduncles and/or
brain stem (the major neuroradiologic sign) and
intention tremor or gait ataxia (the two major clinical
signs) [6]. The prevalence of FXTAS is estimated to be
40–45% overall for males and 16% for females with PM
older than 50 years [60, 61]. The incomplete penetrance
of POI and FXTAS phenotypes makes it difficult to predict
whether a carrier would develop one of the PM-associated
conditions. A major role in determining this penetrance is
certainly due to environmental and genetic/epigenetic
factors that may influence the susceptibility to phenotype
expression. These latter include CGG repeat length,
FMR1 mRNA concentration, XCI, translation of the re-
peat sequence, and any genomic asset able to influence
FMR1 expression [62]. In recent years, it has emerged that
a low-normal repeat number may also have important
clinical implications: a CGG number below 26 can be con-
sidered a risk factor for cognition disability and mental
health problems [63]. Therefore, there is growing aware-
ness that there is a fine homeostatic equilibrium of FMRP
expression levels, so that both high and low numbers of
CGG repeats could alter brain function and alleles previ-
ously considered benign (<26 or 45–54) may lead to
neuropsychiatric manifestations; anyway those are prelim-
inary data that still need to be confirmed by additional
studies. In FXS patients, the CGG trait is expanded (FM),
with a dimension greater than 200 repeats. This expansion
results in transcription silencing and the consequent
absence of FMRP, due to hypermethylation of the CpG
islands adjacent to the expanded trinucleotide repeats
and heterochromatin conformation of the FMR1 pro-
moter region. Conversely, GZ and PM alleles are
unmethylated.
The risk of a PM allele becoming an FM allele is corre-
lated with the number of CGG trinucleotide repeats, with
nearly all alleles with ≥100 repeats expanding to FM in the
next generation when transmitted by the mother; when
the PM is carried by the father, small increases in the tri-
nucleotide repeats may occur in meiosis but typically do
not result in FM [6, 64, 65]. It has been estimated that
66% of maternal and paternal PM alleles change by one or
more repeats in the offspring, even though with a sig-
nificant difference in number of repeat expansions
among maternal and paternal transmission: for alleles with
<70 repeats, paternal alleles have a greater likelihood for
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instability; however, for larger alleles, maternal transmis-
sions are more often unstable [64]. Approximately 17% of
intermediate alleles are unstable, and maternal GZ alleles
may evolve in PM (but not in FM) in future generations [6,
65]. Predictably, GZ alleles ranging from 50 to 54 repeats
are less stable than those with <50 repeats and can more
often evolve into PM ones [65]. Regarding normal-range al-
leles, 0.2% of maternal and 1.5% of paternal alleles exhibit
an increasing size upon transmission [65].
Beyond CGG repeat size, one of the major factors in-
fluencing FMR1 stability is the presence of AGG triplets
interspersed within the FMR1 repeated region. One or
two AGG interruptions are usually interposed with CGG
repeats in FMR1 (most commonly on the 5′ end of the
repeat tract), and this occurs in 94% of the general
population alleles [66]. Conversely, FXS alleles contain-
ing long stretches of uninterrupted CGG triplets at the
3′ end usually do not show any AGG at the 5′ end [66].
Maternal alleles with no AGGs have the greatest risk for
FM expansion, while the presence of even a single AGG
significantly reduces this risk, especially for alleles with
<70 repeats. When the repeat number exceeds 70 trip-
lets, the allele shows high instability even when AGG in-
terruptions are present, and when the CGGs expand
beyond 90, AGG interruptions do not have any ability to
block the triplet growth [64].
A decrease in CGG repeat number through genera-
tions, although rare, is also possible: retractions from
FM to PM and from PM to normal size have both been
widely reported, while retraction from FM to normal
size appears to be sporadic [67–69]. In a study by Nolin
et al., by screening 1040 FMR1 pedigrees, repeat con-
traction had been observed in 2.3% of maternal and
5.7% of paternal transmissions [64]; previous work of the
same research group had already shown a similar rate of
contraction for maternal PM alleles (3,1%) [65]. Retrac-
tion occurs post zygotically because of an excision of a
variable number of trinucleotides, resulting in a mosaic
normal size/GZ/PM/FM [68, 69]. Generally, mosaics
have a higher percentage of the larger allele [69].
Mosaicism is a source of phenotypic variability, and it
can be observed in both sexes, with a higher incidence
in males. The prevalence of mosaicism in FXS males
largely varies among studies, in the range of 12–41% [6,
67]. Both repeat-size mosaicism (e.g., FM/PM, FM/GZ)
and methylation mosaicism have been described; in the
latter, FM has varying degrees of methylation from tissue
to tissue [6, 68–70]. Somatic FM/deletion mosaicism has
also been reported because deletion can occur mitoti-
cally during embryonic cell divisions, usually before the
11th week, with the result of two distinct subpopulations
of cells carrying the deletion and FM alleles [71].
In addition to the FMR1 promoter expansion, a small
number of FXS cases (<1%) are caused by mutation in
the coding region or deletion of the FMR1 gene [6]. Mu-
tations account for approximately 4% of FXS patients
meeting the clinical criteria for FXS but with a normal
range of CGG repeats [72]. Point, missense, nonsense,
frameshift, and UTR region mutations have all been de-
scribed [72–75]. Some of the variants lately identified
still require investigation to definitively classify them as
pathological because the FMRP is sometimes still
present to some degree in carriers [73]. In line with this
genotype-phenotype correlation, a recent study by Teckan
et al. showed that approximately 30–50% of all FMR1 mis-
sense SNPs could be associated with diseases using an in
silico approach [75].
Another important issue to consider, when approaching
a diagnosis in females, is X chromosome inactivation
(XCI), consisting of the silencing of one of the two X chro-
mosomes in mammalian females. Normally, XCI occurs
randomly; however, under particular conditions, preferen-
tial XCI can be observed. In the case of FMR1 mutation
carriers, if the mutated chromosome is preferentially inac-
tivated, FMRP is produced by the normal allele, and the
resulting phenotype would be less severe [76].
Diagnostic procedures
Initially, the diagnosis of FXS was based on the cytogen-
etic evaluation of the presence of FRAXA in peripheral
blood lymphocytes (PBLs). However, this procedure was
time consuming and difficult to interpret, required spe-
cific technical skills and was also unable to distinguish
between FRAXA and the other neighbouring fragile sites
on Xq [55]. To overcome some of these limitations and
improve the detection rate of FRAXA, fluorescence in
situ hybridization (FISH) with DNA probes was then in-
troduced [77].
Cytogenetic analyses were replaced by Southern blot
analysis of DNA from peripheral blood after digestion
with specific restriction endonucleases [78], and finally
by PCR. Southern blot analysis can detect all FMR1 al-
leles, including normal, PM, and FM, and can determine
the methylation status of the FMR1 promoter region;
however, it is time consuming, relatively expensive, and
similarly to the previously used approaches, difficult to
interpret. Standard PCR plus Southern blot analysis has
been considered the gold standard for FMR1 molecular
diagnosis for a long time, even if it provides a low-
resolution estimation of the repeat number [66, 79, 80].
Standard PCR, based on the direct amplification of the
CGG-repeat using flanking primers, is faster and highly
sensitive to detect FMR1 repeats in the normal and PM
range; however, it could only reveal alleles with up to
~300 repeats in males and up to ~160 repeats in females
and it therefore fails to identify the large CGG expan-
sions (e.g. more than 300 CGGs) [81].
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The limitations of the PCR plus southern Blot technique
lead to the development of new PCR-based procedures
able to detect all FMR1 alleles. Triplet primed PCR (TP-
PCR) was designed: it is a procedure in which the forward
PCR primer is located upstream the CGG region and the
other overlaps the CGG repeat and the adjacent unique
sequence; after PCR cycles, the CGG repeat number can
be determined by fragment sizing of PCR amplicons using
capillary electrophoresis [66, 82]. TP-PCR is the evolution
of previous PCR protocols; this procedure allows the sim-
ultaneous amplification of both the full-length FMR1 al-
leles (using PCR primers flanking the repeated region) and
CGG triplets (using a third primer, complementary to the
FMR1 triplet repeat region) in the same PCR reaction.
TP-PCR-based procedures became the gold standard for
the first level assessment of FXS and can detect the ex-
panded allele even in mosaic fashion. This PCR based kit
also allows the detection of AGG interruptions.
As the second-level analysis in the diagnostic flow-
chart, CGG methylation testing can be performed to
evaluate FMRP silencing. Dedicated kits, such as the
Methylation-Sensitive Long-Range PCR (MS-LR-PCR)
kit, have been developed to measure the methylation
fraction of each FMR1 allele, using DNA after digestion
with methylation-sensitive restriction enzymes [83]. This
approach is also very useful to identify those rare FM
unmethylated males that are asymptomatic carriers of a
pathologic allele [83].
Finally, the finding of the loss of function mutations of
FMR1 as causative of FXS prompted the development of
specific molecular techniques. FMR1 sequence analysis
and MLPA must therefore be offered to patients with a
clinical phenotype highly suggestive of FXS but with a
normal range of CGG repeats. Additional testing to
identify intragenic deletions or duplications is required
when PCR amplification fails, suggesting a possible ex-
onic or whole-gene anomaly [6].
Prenatal FMR1 testing
FXS molecular tests are usually performed postnatally
on PBLs in the presence of the appropriate clinical cri-
teria described in the clinical section. Moreover, it is also
possible to perform a prenatal test of FXS using LR-
PCR-based protocols on DNA from either chorionic villi
or amniocytes. Currently, according to ACMG (American
College of Medical Genetics) and ACOG (American
Congress of Obstetricians and Gynaecologists) guidelines,
FMR1 prenatal testing should be offered to couples with a
personal or familial history of the following:
1. FXS- or FX-related disorders
2. Unexplained ID or developmental delay
3. Isolated cognitive impairment
4. Autism
5. Idiopathic familiar POI or elevated FSH at age
<40 years
6. Isolated cerebellar ataxia with tremor
In addition, given the high incidence of FXS in the
general population, a consistent number of genetic
health professionals have supported prenatal testing for
all women who request the analysis, regardless of their
personal/familial history [84]. However, it should be
taken into consideration that FMR1 test interpretation
could be complicated by different problems; in particu-
lar, the presence of GZ alleles is very difficult to be inter-
preted and counselled because the risk of expansion,
although very low, cannot be excluded [76]. The prenatal
findings of FM females are also complex because the
XCI pattern can modify the clinical phenotype. More-
over, the presence of post-zygotic mosaicism can compli-
cate the diagnosis. This phenomenon can generate false
results, especially in prenatal screening, because the clin-
ical phenotype of the proband would not be available
until birth.
Finally, it has been suggested that GZ and PM carriers
with a positive family history of FX-associated disorders
are at higher risk of expansion [65]. This is at least partly
due to the presence and number of AGG interruptions
in the parental allele. AGG trinucleotide repeats geno-
typing can be therefore offered to determine the number
and location of AGG trinucleotide interruptions within
the tract of CGG repeats of FMR1, particularly in female
carriers of a GZ or a small PM allele [6, 65, 85].
Considering all of these issues, for couples who re-
quest FXS screening, the ideal test should be proposed
in the preconception period: this could be advantageous
because the couple will be allowed to make conscious
reproductive decisions. In addition, the parents would
also receive useful information for their personal health.
Indeed, the identification of premutated females (which
are at risk for POI) may allow a more effective repro-
ductive intervention in those desiring a pregnancy.
Newborn screening for FXS has been proposed [86, 87],
even if its application remains controversial. Although
FXS is a relatively frequent disorder, and there would be
the possibility to apply a quite sensitive and specific test, a
real benefit of testing is lacking because there is no specific
therapy currently to treat children, and treatment is essen-
tially symptom based. In 2014, Godler et al. proposed a
screening protocol where FMR1 methylation analysis
would be used as the first-line test to selectively identify
only FM carriers, followed by a triple-primed CGG-based
test to confirm the positive results [87]. Nonetheless, to
date, newborn screening for FXS is not performed in any
country. The quest for a blood-based biomarker of FXS is
currently underway [74]. Finding a simple and low-cost
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biochemical test would pave the way to include an FXS
test in routine newborn screening.
Patient management: therapeutic strategies and social
issues
FXS emerges as a complex disease with a primary neuro-
psychiatric involvement but potentially affects more than
one apparatus, therefore needing a large-scale intervention
able to address all the physical, psychological and social
implications of the disease. Treatment plans should be
individualized based on the symptoms and age-related
comorbidities of each individual. Speech and language
therapy must be recommended to children, especially in
that with early diagnosis. Most males show in fact moder-
ate to severe delay in communication skills, while the
communication skills of females are considerably less af-
fected [48]. Behavioural therapy is another useful tool that
helps normalize some of the symptoms, and it has been
reported to be an effective approach for aggression in 71%
of patients [37]. Therapy techniques that have been vali-
dated for autism are often helpful for FXS but must be
modified based on the particular ASD features in FXS
phenotype [88]. Physical therapy is needed in some cases,
and occupational therapy must be offered to adults. A
study by Martin et al., collecting males and females with
FXS aged 0–63, showed that 72% of males and 47% of fe-
males receive one or more non-pharmacological therapy
service [89]. The most common service for both males
and females is speech–language therapy (68% males, 42%
females), followed by occupational therapy (59% males,
30% females), physical therapy (25% males, 10% females),
and behaviour management therapy (21% males, 6% fe-
males). Overall, males are more likely to receive therapy
services as well as a greater number of services than fe-
males. All these strategies are mostly adopted during
childhood and an age-related decline of therapies occurs
for both males and females, with the use of services peak-
ing by 11 years and essentially non-existent after the age
of 20 [89].
Pharmacologic therapy may be recommended to im-
prove behaviour problems (such as aggression, anxiety,
hyperactivity, problems with impulse control, and poor
attention span) and also to treat more severe disorders,
such as ADHD or depression [8, 52]. The most common
classes of medication used by FXS patients are selective
serotonin reuptake inhibitors (SSRIs) and atypical anti-
psychotics, with SSRIs use being more common among
females than males [90]. In approximately 60% of pa-
tients, drug treatment for psychological issues helped
the remission of some symptoms; in particular, stimu-
lants can be used to improve attention and hyperactivity,
SSRIs for anxiety, alpha-agonists for hyperactivity and
overarousal, and antipsychotics for irritable and aggres-
sive behaviours [91]. Drugs should anyway always be
combined with non-pharmacological strategy to reach
the best outcome. For ADHD in particular, it has been
demonstrated that the early diagnosis and treatment play
a role in improving both concurrent and long-term so-
cial functioning [33].
Lithium has been proposed as possible treatment, and
in 2008, a pilot add-on trial has been conducted to
evaluate the safety and efficacy of this drug in FXS pa-
tients. The results showed a significant improvement in
hyperactivity, inappropriate speech, aggression, abnor-
mal vocalizations, self-abuse, work refusal, outbursts,
over-emotionality, anxiety, mood swings, tantrums, persev-
eration, crying, and maladaptive behaviour after 2 months
of treatment [92]. Scores on the Clinical Global Improve-
ment Scale were also significantly enhanced, and positive
responses were distributed across all the age ranges of the
study cohort, suggesting that both children and young
adults with FXS can benefit from lithium treatment [92].
New targeted treatments for FXS (mGluR5 antagonists,
GABA A and B agonists, minocycline) are now being
studied. In Fmr1 knockout (KO) mice, the glutamatergic
receptors signalling and/or localization is enhanced. New
studies that try to reduce excitatory neurotransmission by
antagonism of group I metabotropic glutamate receptors
(mGluRs), particularly mGluR5, are still underway [93]. By
now, studies conducted on Fmr1 KO mice demonstrated
that the reduction of mGluR5 levels can normalize protein
synthesis, dendritic spines, and some behaviour [94]. In
FXS, an insufficient inhibitory GABAergic function has
also been reported. A positive modulation of GABA(A)
receptors has been demonstrated to improve some be-
havioural and neurophysiological alterations in Fmr1
KO mice [95]. Drugs modulating GABA signalling could
therefore be an effective therapy. Minocycline is an FDA-
approved treatment for acne and is known to have inhibi-
tory effects on matrix metalloproteinase-9 activity. It is
currently under study for FXS treatment and seems to
have its greatest effect in young children, where it
strengthens synaptic connections and enhances cognitive
development [96].
Moreover, specific pharmacological intervention is
needed to address common complications, such as epi-
lepsy, metabolic disorders and hypertension.
Going beyond treatment, an important issue to con-
sider in the management of FXS patients is the psycho-
logical health of their parents and caregivers; both have
to take care of these complicated patients in different
ways, and both have been proven to suffer psychological
consequences.
Although a diagnosis of FXS is beneficial to the family
for establishing the reason why a child has cognitive defi-
cits and/or behavioural problems, all the family members
have to cope with the disease and the derived stress. Men-
tal and physical health problems especially affect families
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with higher stress levels, and these families often have an
impaired ability to manage the difficult behaviours and
physical problems of their children. This leads to an in-
creased need for intervention with caregivers at the family
level [37]. On the other hand, caregivers of patients with
FXS are more likely to develop comorbidities such as
anxiety, depression, stress, and sleep disorders than the
caregivers of patients without FXS and are also more likely
to receive medications for these conditions [97, 98].
Despite the relatively low incidence of FXS, this dis-
ease has a significant impact on parents, caregivers and
entire society within which the patient lives. The poor
social functioning of FXS individuals, together with the
need for medication and non-pharmacological interven-
tion, has important consequences in terms of the costs
and resources employed. The percentage of working
FXS patients varies largely with studies, in the range of
20–70%, with females being more frequently employed
than males [97, 98]. Predictably, the higher functioning
employed group of FXS patients also has lower direct
healthcare costs [98]. It has been estimated that the eco-
nomic burden of FXS in Europe is significant, with a
mean annual cost per patient reaching up to €58,862
[97]. The patient cost is even higher in the USA, where
it has been estimated to be as high as $14,677 every
month [98].
Conclusions
FXS is a well-known condition; however, most of the
studies thus far have focused on its neuropsychiatric
features. This review was aimed to provide an extensive
overview of both the clinical and molecular features of
this syndrome. Unfortunately, some of the studies cited
in this work have limitations, such as the paucity of
patients enrolled and the bias due to the collection of
data in a single-country population, which may not be
representative of the average global FXS population.
Most of the studies collected focus on FXS children;
however, in recent years, insight into the adult presenta-
tion of the disease has progressively increased. Further-
more, only a few studies have been conducted including
non-Caucasian populations. Pharmacological treatment in
FXS is essentially symptom based, but the growing under-
standing of the molecular and biological mechanisms of
the disease are paving the way to targeted therapy, which
might reverse the effects of FMRP deficiency and be a real
cure for the disease itself, not just its symptoms.
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